Clinical Trial

Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia

Study acronym: Immune-AML
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 20, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, prospective, translational study, to evaluate the immunogenic profile of AML cases according to immune checkpoint molecule expression.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-12-21; most recent amendment 2024-09-18.
Status change: Recruiting → Active, Not Recruiting 2024-09-18
Status change: Not Yet Recruiting → Recruiting 2020-04-20
Trial Details
NCT Number NCT03789981
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions Acute Myeloid Leukemia
Enrollment 75 participants
Start Date 2019-07-19
Primary Completion 2024-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-20